2ª Reunión Científica 2014 - "Post-SABCS 2013 - Buenos Aires"
AMA (Av. Santa Fe 1171) - 26 de junio de 2014, 19 hs

Coordinador: Prof. Dr. Roberto Elizalde
Secretaria: Dra. Gabriela Candás

- **PRIMERA SESIÓN (15')**
  Presentador: Dr. Francisco Terrier

  1) Pathology and biology of early lesions
  Stuart J. Schnitt, MD
  Beth Israel Deaconess Medical Center and Harvard Medical School. Boston, MA

  2) Who should receive preventive therapy?
  Jack Cuzick, PhD
  Queen Mary University of London. London, UK

  3) Breast SERMs and Als - Prevention of all types of breast cancer
  Powel H. Brown, MD, PhD
  UT MD Anderson Cancer Center. Houston, TX

- **SEGUNDA SESIÓN (15')**
  Presentador: Dra. Astrid Margossian

  1) Genomics variation underlying breast cancer heterogeneity
  Laura J. van ’t Veer, PhD
  University of California San Francisco. San Francisco, CA

  2) Translational research highlights for 2013
  Charles M. Perou, PhD
  University of North Carolina at Chapel Hill. Chapel Hill, NC

- **TERCERA SESIÓN (15')**
  Presentador: Dr. Luis Barbera

  1) The role of sentinel lymph node biopsy before versus after neoadjuvant chemotherapy
  Lisa A. Newman, MD, MPH, FACS
  University of Michigan Comprehensive Cancer Center. Ann Arbor, MI
2) Local-regional management issues for the radiation. Oncologist in the neoadjuvant chemotherapy setting
Barbara Fowble, MD, FACR, FASTRO
University of California San Francisco. San Francisco, CA

\[\text{CUARTA SESIÓN (15')}\]
**Presentador:** Dr. Jorge Martín

1) Adjuvant Bisphosphonate Therapy in Breast Cancer
Michael Gnant, MD, FACS
Medical University of Vienna. Vienna, AT

2) First results of the International Breast cancer Intervention Study II (IBIS-II): A multicentric prevention trial of anastrazole versus placebo in postmenopausal women at increased risk of developing breast cancer
Jack Cuzick, PhD
Queen Mary University of London. London, UK

\[\text{QUINTA SESIÓN (15')}\]
**Presentador:** Dr. Federico Coló

1) 10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients
Thomas Julian, MD
UT MD Anderson Cancer Center. Houston, TX

2) Inflammatory Breast Cancer: Multidisciplinary management and evolving therapies
Massimo Cristofanilli, MD
Thomas Jefferson University. Philadelphia. PA

\[\text{SEXTA SESIÓN (15')}\]
**Presentador:** Dr. Daniel H. Allemand

1) Local Therapy in the Molecular Era: Relevant or Relic?
Monica Morrow, MD, FACS
Memorial Sloan-Kettering Cancer Center. New York, NY

2) Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial
Rajendra A. Badwe, MD
Tata Memorial Centre, Mumbai. Maharashtra, IN